#!/usr/bin/env python3
"""Add the June 10, 2026 Alzheimer clinical-trials article to the content seed."""

from __future__ import annotations

import json
from pathlib import Path


CONTENT_PATH = Path("mindful_diabetes_wp_parse_outputs/wp_migration_outputs/flask_content_seed.json")
IMAGE_BRIEF_PATH = Path("docs/blog-image-briefs/2026-06-10-alzheimers-clinical-trials-landscape.md")


TITLE = "Inside the Alzheimer’s Clinical-Trial Landscape: What Researchers Were Testing in June 2026"
SLUG = "alzheimers-clinical-trials-june-2026"
DATE = "2026-06-10 09:00:00"
EXCERPT = (
    "A careful June 10, 2026 snapshot of Alzheimer’s clinical trials, including how the trial count was built, "
    "what studies were recruiting, where trials were located, what interventions were being tested, and what "
    "research participation can and cannot promise."
)


IMAGES = [
    {
        "slot": "hero",
        "filename": "alzheimers-clinical-trials-june-2026-hero.webp",
        "size": "1600 x 900",
        "width": 1600,
        "height": 900,
        "alt": "Older adults, a care partner, and a clinician discuss an Alzheimer’s clinical trial in a warm research clinic with brain scans and blood samples nearby.",
        "title": "Alzheimer’s clinical-trial research visit",
        "description": "Hero image for a Mindful Diabetes article explaining the Alzheimer’s clinical-trial landscape as of June 10, 2026.",
        "caption": "Alzheimer’s trials are structured research questions that may involve people, care partners, clinicians, biomarkers, data, and follow-up over time.",
        "placement": "Hero image at the top of the article.",
        "prompt": "A warm, modern Alzheimer’s clinical-research environment showing a diverse group of older adults, a care partner, a clinician, brain imaging, blood samples, and research data as parts of one coordinated study. Hopeful through careful scientific work, not through cure promises.",
    },
    {
        "slot": "landscape",
        "filename": "alzheimers-clinical-trial-landscape-pathways.webp",
        "size": "1400 x 933",
        "width": 1400,
        "height": 933,
        "alt": "A branching scientific illustration connects Alzheimer’s research pathways including neurons, immune cells, blood vessels, mitochondria, wearables, walking, biomarkers, and care.",
        "title": "Many pathways in Alzheimer’s clinical research",
        "description": "Supporting image for a section showing Alzheimer’s clinical trials as multiple research pathways rather than one simple pipeline.",
        "caption": "The June 2026 landscape included treatment, diagnosis, prevention, devices, lifestyle, and care research rather than a single path toward one answer.",
        "placement": "Section introducing the June 10 trial landscape.",
        "prompt": "A clear visual showing several research pathways branching from Alzheimer’s disease: amyloid, tau, immune biology, metabolism, synaptic function, vascular health, devices, lifestyle, biomarkers, and care. Avoid embedded labels.",
    },
    {
        "slot": "phases",
        "filename": "alzheimers-clinical-trial-phases-pathway.webp",
        "size": "1400 x 933",
        "width": 1400,
        "height": 933,
        "alt": "A warm clinical research pathway moves from a small safety visit to biomarker review, a larger multicenter study, and long-term monitoring, with side paths where studies may stop.",
        "title": "Clinical-trial phases as research questions",
        "description": "Supporting image for a section explaining Phase 1 through Phase 4 and why later phases do not guarantee success.",
        "caption": "Trial phases change the question being asked, from early safety and dosing to larger tests of benefit and longer-term monitoring.",
        "placement": "Section explaining trial phases and design terms.",
        "prompt": "A visually attractive pathway from Phase 1 through Phase 4, showing increasing participant scale and changing research questions. Include cues that studies may pause or change direction.",
    },
    {
        "slot": "global-locations",
        "filename": "alzheimers-trial-global-locations-map-concept.webp",
        "size": "1400 x 933",
        "width": 1400,
        "height": 933,
        "alt": "Researchers review a warm conceptual world map with clustered clinical-trial site markers in North America, Europe, East Asia, and fewer markers in other regions.",
        "title": "Global Alzheimer’s trial locations and access gaps",
        "description": "Supporting image for a geographic section discussing public trial-location records and unequal access to Alzheimer’s studies.",
        "caption": "ClinicalTrials.gov location records showed heavy representation in North America, Europe, and East Asia, with much lighter representation in many other regions.",
        "placement": "Section on where the trials were taking place.",
        "prompt": "A warm global clinical-research map concept showing trial sites across multiple regions, with visual acknowledgement that access is uneven. Do not create a misleading literal map unless built from actual data.",
    },
    {
        "slot": "participation",
        "filename": "alzheimers-research-participation-visit.webp",
        "size": "1400 x 933",
        "width": 1400,
        "height": 933,
        "alt": "An older adult and care partner move through Alzheimer’s research visit steps including a tablet task, blood draw, imaging suite, infusion chair, wearable, and clinician conversation.",
        "title": "What Alzheimer’s research participation may involve",
        "description": "Supporting image for a section explaining practical trial participation steps such as testing, blood draws, imaging, treatment visits, monitoring, and care-partner conversations.",
        "caption": "Participation can involve screening, cognitive testing, blood work, imaging, treatments or devices, diaries, wearables, travel, and care-partner interviews.",
        "placement": "Section on what joining a study can involve.",
        "prompt": "A respectful research-participation scene showing cognitive testing, a blood draw, MRI or PET imaging, medication or infusion, a wearable, and a care-partner conversation.",
    },
    {
        "slot": "evidence-pathway",
        "filename": "alzheimers-research-question-to-evidence.webp",
        "size": "1400 x 933",
        "width": 1400,
        "height": 933,
        "alt": "A translational research pathway moves from a neuron idea and lab evidence to early safety monitoring, controlled clinical testing, data review, and cautious clinical discussion.",
        "title": "From research question to clinical evidence",
        "description": "Supporting image for a closing section explaining how Alzheimer’s studies build evidence, including negative or redirected findings.",
        "caption": "Clinical trials turn promising ideas into structured evidence, and sometimes the most useful result is learning why an approach should change direction.",
        "placement": "Closing section on what the current pipeline says about Alzheimer’s research.",
        "prompt": "A translational pathway showing biological idea, laboratory evidence, early safety study, controlled clinical testing, data review, and possible future clinical use, with side branches for negative findings.",
    },
]


def figure(index: int) -> str:
    image = IMAGES[index]
    return f"""
<figure data-image-slot="{image['slot']}" data-description="{image['description']}">
  <img data-description="{image['description']}" width="{image['width']}" height="{image['height']}" src="/static/uploads/2026/06/{image['filename']}" alt="{image['alt']}" title="{image['title']}" loading="lazy" />
  <figcaption>{image['caption']}</figcaption>
</figure>
""".strip()


CONTENT_HTML = f"""
<img width="1600" height="900" src="/static/uploads/2026/06/{IMAGES[0]['filename']}" alt="{IMAGES[0]['alt']}" title="{IMAGES[0]['title']}" data-description="{IMAGES[0]['description']}" loading="lazy" />
<h2>Alzheimer’s Trials Are Not One Pipeline</h2>
<p>When people hear “Alzheimer’s clinical trials,” it can sound as if every study is testing the same thing: one medicine, one target, one race toward approval. The June 2026 landscape was more complicated and more useful than that. Researchers were asking whether disease biology could be slowed, whether treatment could begin earlier, whether diagnosis could become more accessible, whether symptoms and daily function could be supported more humanely, and whether the field could learn which person is most likely to benefit from which approach.</p>
<p>This article is a dated snapshot, not a permanent scoreboard. ClinicalTrials.gov records change as sponsors update recruitment status, locations, completion dates, eligibility, and outcomes. For that reason, the numbers below use a conservative rule: the article counts only public registry records whose first posting and latest public update were both available by <strong>June 10, 2026</strong>. Records updated after that date were preserved in a separate exclusions file rather than quietly treated as June 10 facts.</p>
<p>The result is not “every Alzheimer’s study in the world.” It is a reproducible ClinicalTrials.gov snapshot designed to help readers understand what the field was trying to accomplish, why trial totals differ, and how to think about participation without mistaking research for guaranteed treatment.</p>

<h2>Why the Number Depends on What We Count</h2>
<p>Different Alzheimer’s trial totals can all be honest and still disagree. A drug-pipeline review may count only pharmacologic studies. A registry search may include devices, diagnostics, lifestyle studies, caregiver programs, and observational cohorts. One source may include recruiting studies only. Another may include active but no longer recruiting trials. Some searches include Alzheimer’s disease alone; others include Alzheimer’s disease and related dementias, mild cognitive impairment, subjective cognitive concerns, or prevention studies.</p>
<p>For this article, the broad snapshot started with the <a href="https://clinicaltrials.gov/api/v2/studies?query.cond=Alzheimer+Disease&amp;filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&amp;pageSize=1000&amp;format=json&amp;countTotal=true" target="_blank" rel="noopener">ClinicalTrials.gov API query for Alzheimer Disease records with active recruitment statuses</a>. It then deduplicated by NCT number and retained only records first posted on or before June 10, 2026, with a latest public update posted on or before June 10, 2026. The full methodology is documented in <code>docs/research/2026-06-10-alzheimers-clinical-trials-methodology.md</code>.</p>
<p>Using that definition, the broad snapshot contained <strong>878 relevant registered studies</strong>: <strong>592 interventional</strong> and <strong>286 observational</strong>. A narrower “participation-now” subset contained <strong>671 studies</strong> that were recruiting, not yet recruiting, or enrolling by invitation and had at least one public location entry. The distinction matters because a study can be scientifically active but closed to new volunteers.</p>

<table>
  <caption>Table 1. June 10, 2026 ClinicalTrials.gov Alzheimer’s snapshot</caption>
  <thead>
    <tr>
      <th>Measure</th>
      <th>Count</th>
      <th>What it represents</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Broad snapshot</td>
      <td>878</td>
      <td>Active-status Alzheimer Disease records, deduplicated by NCT number, first posted and last updated by June 10, 2026.</td>
    </tr>
    <tr>
      <td>Interventional studies</td>
      <td>592</td>
      <td>Studies assigning a drug, device, behavioral program, procedure, diagnostic strategy, or other intervention.</td>
    </tr>
    <tr>
      <td>Observational studies</td>
      <td>286</td>
      <td>Studies observing biomarkers, cognition, care, risk, progression, or real-world outcomes without assigning an intervention.</td>
    </tr>
    <tr>
      <td>Participation-now subset</td>
      <td>671</td>
      <td>Recruiting, not-yet-recruiting, or invitation-enrolling records with public locations.</td>
    </tr>
    <tr>
      <td>Excluded after cutoff</td>
      <td>189</td>
      <td>Records first posted after June 10 or updated after June 10 whose exact June 10 status was not reconstructed.</td>
    </tr>
  </tbody>
</table>

{figure(1)}

<h2>A June 10, 2026 Snapshot of the Field</h2>
<p>The snapshot makes one point immediately: Alzheimer’s clinical research was much broader than anti-amyloid drug trials. Diagnostics, imaging, biomarkers, care programs, behavior studies, quality-of-life research, lifestyle interventions, devices, and observational cohorts made up a large share of the public registry landscape. Drug-pipeline analyses available before the cutoff reached a different number because they asked a narrower question. For example, the <a href="https://www.alz.org/news/2026/alzheimers-disease-drug-development-pipeline-is-growing" target="_blank" rel="noopener">Alzheimer’s Association summarized a May 5, 2026 drug-pipeline analysis</a> with an index date of January 1, 2026, reporting 192 Alzheimer’s drug trials assessing 158 drugs; it also noted that non-pharmacologic approaches such as devices, lifestyle interventions, caregiver programs, gene therapies, and stem cell therapies were outside that drug-pipeline count.</p>
<p>In practice, this means the answer to “How many Alzheimer’s trials are there?” should always be followed by “What did we count?” The 878-study number below is a broad ClinicalTrials.gov active-status snapshot. The 192-trial number from the drug-pipeline literature describes a drug-development subset. Both are useful; they are not interchangeable.</p>

<table>
  <caption>Table 2. Major research categories in the broad snapshot</caption>
  <thead>
    <tr>
      <th>Research category</th>
      <th>Included studies</th>
      <th>Participation-now studies</th>
      <th>Typical question</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Diagnostics, imaging, and biomarkers</td>
      <td>378</td>
      <td>299</td>
      <td>Can blood, imaging, speech, gait, retinal, digital, or fluid markers improve detection, staging, monitoring, or enrollment?</td>
    </tr>
    <tr>
      <td>Care, behavior, and quality of life</td>
      <td>282</td>
      <td>214</td>
      <td>Can symptoms, function, caregiver burden, sleep, agitation, home support, or communication be improved?</td>
    </tr>
    <tr>
      <td>Other interventional treatment research</td>
      <td>72</td>
      <td>52</td>
      <td>Can a treatment or clinical strategy affect symptoms, function, or disease-related outcomes?</td>
    </tr>
    <tr>
      <td>Lifestyle and multidomain</td>
      <td>48</td>
      <td>39</td>
      <td>Can exercise, sleep, diet, cognitive training, social engagement, or combined risk-reduction programs support brain health?</td>
    </tr>
    <tr>
      <td>Devices and brain stimulation</td>
      <td>34</td>
      <td>28</td>
      <td>Can ultrasound, stimulation, sensory entrainment, or other device approaches safely influence brain function or biomarkers?</td>
    </tr>
    <tr>
      <td>Amyloid-targeting approaches</td>
      <td>22</td>
      <td>11</td>
      <td>Can amyloid biology be changed safely, earlier, or in more precisely selected groups?</td>
    </tr>
    <tr>
      <td>Tau-targeting approaches</td>
      <td>13</td>
      <td>6</td>
      <td>Can tau accumulation, spread, or tau-related injury be modified?</td>
    </tr>
    <tr>
      <td>Synapses and neuronal communication</td>
      <td>9</td>
      <td>6</td>
      <td>Can neuronal signaling, synaptic resilience, or cognition-related pathways be supported?</td>
    </tr>
    <tr>
      <td>Vascular and blood-brain barrier</td>
      <td>6</td>
      <td>5</td>
      <td>Can blood flow, barrier function, vascular risk, or vascular-brain overlap be measured or changed?</td>
    </tr>
    <tr>
      <td>Neuroinflammation and immune biology</td>
      <td>4</td>
      <td>3</td>
      <td>Can immune signaling be adjusted without disrupting useful repair responses?</td>
    </tr>
    <tr>
      <td>Metabolism, insulin signaling, and cellular energy</td>
      <td>3</td>
      <td>3</td>
      <td>Can metabolic or energy-related pathways inform prevention, diagnosis, or treatment?</td>
    </tr>
  </tbody>
</table>

<h2>Where the Trials Were Taking Place</h2>
<p>ClinicalTrials.gov location records do not tell us everything about access. A registry may list several sites for a study while enrollment is paused at some locations, or a country may have one large urban academic center but little practical access for rural communities. Still, public locations help show where the visible trial infrastructure was concentrated.</p>
<p>In the broad snapshot, <strong>350 studies had at least one United States site</strong>, while <strong>458 studies listed sites outside the United States without a U.S. site</strong>. Only <strong>41 studies were multinational</strong> by country count. By public location entries, the United States dominated the dataset, followed by China, Japan, Canada, France, Spain, the United Kingdom, Italy, South Korea, and Germany. Regionally, North America, Europe, and East Asia carried most listed locations.</p>

{figure(3)}

<table>
  <caption>Table 3. Geographic distribution from public location records</caption>
  <thead>
    <tr>
      <th>Country or region</th>
      <th>Unique studies</th>
      <th>Public location entries</th>
    </tr>
  </thead>
  <tbody>
    <tr><td>United States</td><td>350</td><td>2,331</td></tr>
    <tr><td>China</td><td>111</td><td>542</td></tr>
    <tr><td>France</td><td>73</td><td>179</td></tr>
    <tr><td>Canada</td><td>56</td><td>202</td></tr>
    <tr><td>Spain</td><td>48</td><td>144</td></tr>
    <tr><td>Italy</td><td>47</td><td>106</td></tr>
    <tr><td>United Kingdom</td><td>32</td><td>126</td></tr>
    <tr><td>South Korea</td><td>19</td><td>94</td></tr>
    <tr><td>Taiwan</td><td>19</td><td>32</td></tr>
    <tr><td>Australia</td><td>18</td><td>77</td></tr>
    <tr><td>North America</td><td>408</td><td>2,535</td></tr>
    <tr><td>Europe</td><td>317</td><td>926</td></tr>
    <tr><td>East Asia</td><td>174</td><td>926</td></tr>
  </tbody>
</table>

<p>The gaps matter. Rural communities may face long travel times even in countries with many listed sites. Lower- and middle-income countries were much less visible in this ClinicalTrials.gov snapshot. Many biomarker-heavy studies also require PET imaging, MRI, specialized blood or cerebrospinal-fluid testing, or memory-clinic infrastructure. That makes geography more than a map; it shapes who can realistically participate and whose experience becomes part of the evidence.</p>

<h2>What Researchers Were Trying to Change</h2>
<p>The major target areas tell us what the field believed was worth testing in June 2026. They do not prove that any intervention works. A trial is a structured question.</p>
<h3>Amyloid-targeting approaches</h3>
<p>Amyloid remained important because anti-amyloid antibodies had shown that plaque biology can be modified in selected people, but plaque reduction is not the same as reversing dementia. Representative records in the snapshot included <a href="https://clinicaltrials.gov/study/NCT03887455" target="_blank" rel="noopener">NCT03887455</a>, a Phase 3 lecanemab study in early Alzheimer’s disease; <a href="https://clinicaltrials.gov/study/NCT04468659" target="_blank" rel="noopener">NCT04468659</a>, the AHEAD 3-45 lecanemab prevention study in preclinical Alzheimer’s disease; and <a href="https://clinicaltrials.gov/study/NCT05026866" target="_blank" rel="noopener">NCT05026866</a>, a Phase 3 donanemab study in preclinical Alzheimer’s disease.</p>
<p>These trials show why disease stage matters. A trial in preclinical Alzheimer’s disease is asking whether intervention before clear symptoms can change biomarkers or later cognitive trajectory. A trial in early symptomatic disease is asking a different question. Safety monitoring also matters. Anti-amyloid approaches can involve amyloid-related imaging abnormalities, often called ARIA, which can include brain swelling or bleeding changes seen on MRI. Many cases are asymptomatic, but some can be serious. Readers who want the biology in more depth can start with our January article, <a href="/amyloid-plaques-alzheimers-research/">Amyloid Plaques Are Not the Whole Story</a>.</p>
<h3>Tau-targeting approaches</h3>
<p>Tau remained a central target because tau patterns often track more closely with neuronal injury and symptoms than amyloid burden alone, while tau biology itself remains complicated. Representative snapshot records included <a href="https://clinicaltrials.gov/study/NCT06268886" target="_blank" rel="noopener">NCT06268886</a>, a Phase 2 anti-MTBR tau monoclonal antibody study in early Alzheimer’s disease, and <a href="https://clinicaltrials.gov/study/NCT06602258" target="_blank" rel="noopener">NCT06602258</a>, a Phase 2 E2814 study with concurrent lecanemab in early Alzheimer’s disease.</p>
<p>Tau trials may test antibodies, vaccines, aggregation strategies, or approaches meant to affect tau spread or downstream neuronal stress. Our earlier articles on <a href="/tau-microglia-neuronal-stress/">tau, microglia, and neuronal stress</a> and <a href="/tau-pet-imaging-alzheimers/">tau PET imaging</a> explain why tau imaging changed the research picture without making tau a simple one-number answer.</p>
<h3>Neuroinflammation and immune biology</h3>
<p>Inflammation is not merely “bad” in the brain. Microglia and astrocytes can respond to injury, contain damage, clear debris, and also contribute to harmful signaling depending on timing, cell state, genetics, and disease stage. The goal in immune-oriented trials is usually to adjust a response, not to turn immunity off. In this conservative snapshot, immune-labeled trials were few by the article’s heuristic categories, but broader drug-pipeline analyses published before the cutoff reported growing attention to inflammation and immune dysfunction. Our December article on <a href="/microglia-astrocytes-alzheimers/">microglia and astrocytes</a> is a useful companion.</p>
<h3>Metabolism, insulin signaling, and cellular energy</h3>
<p>This is where the Mindful Diabetes lens matters. Researchers test metabolic approaches because brain health depends on energy use, vascular function, insulin signaling, inflammation, and cellular resilience. That does not mean a diabetes medicine should be described as an Alzheimer’s treatment unless clinical trials establish that for a defined population.</p>
<p>Representative snapshot records included <a href="https://clinicaltrials.gov/study/NCT04098666" target="_blank" rel="noopener">NCT04098666</a>, a metformin prevention study, and <a href="https://clinicaltrials.gov/study/NCT07200622" target="_blank" rel="noopener">NCT07200622</a>, a Phase 2 oral semaglutide study listed as not yet recruiting in the conservative snapshot. These examples show why repurposed medicines can be attractive: prior use in another condition may provide safety and dosing knowledge, but Alzheimer’s benefit still has to be tested directly. Related Mindful Diabetes background includes <a href="/insulin-resistance-cognitive-decline/">insulin resistance and cognitive decline</a>, <a href="/type-3-diabetes/">Type 3 Diabetes</a>, and <a href="/connecting-diabetes-and-alzheimers/">the diabetes-Alzheimer’s connection</a>.</p>
<h3>Synapses, vascular biology, devices, lifestyle, diagnostics, and care</h3>
<p>Some trials ask whether neuronal communication or synaptic resilience can be supported. Others test cerebral blood flow, blood-brain barrier strategies, vascular risk, or mixed Alzheimer’s and vascular pathology. Device studies in the snapshot included ultrasound, light-and-sound stimulation, transcranial stimulation, and other neuromodulation approaches; for example, <a href="https://clinicaltrials.gov/study/NCT05983575" target="_blank" rel="noopener">NCT05983575</a> studied low-intensity pulsed ultrasound in early Alzheimer’s disease, while <a href="https://clinicaltrials.gov/study/NCT06595511" target="_blank" rel="noopener">NCT06595511</a> studied combined 40 Hz audio-visual stimulation and cognitive games.</p>
<p>Lifestyle and multidomain studies are essential but difficult to interpret. Blinding is hard. Adherence varies. Exercise, diet, sleep, social support, medication changes, and cognitive stimulation may change together. Effects may be modest and may require long follow-up. That does not make lifestyle research weak; it means it asks human, whole-life questions that are harder to isolate. Our posts on <a href="/sleep-aging-brain-dementia-risk/">sleep and the aging brain</a> and <a href="/prevent-type-3-diabetes-with-exercise/">active bodies and brain health</a> connect to this part of the field.</p>
<p>Diagnostic and biomarker studies were the largest category in this snapshot. Studies such as <a href="https://clinicaltrials.gov/study/NCT06122415" target="_blank" rel="noopener">NCT06122415</a>, the Swedish BioFINDER Memory Clinic Study, show how blood biomarkers, imaging, and longitudinal follow-up can support better staging and trial enrollment. Biomarker research can improve detection and monitoring without directly treating disease. For background, see our May article on <a href="/alzheimers-blood-biomarkers/">blood biomarkers</a> and our April article on <a href="/alzheimers-research-blood-tests-tau-trials/">blood clues, tau timelines, and trial design</a>.</p>
<p>Care, behavior, and quality-of-life research was also prominent. <a href="https://clinicaltrials.gov/study/NCT05397639" target="_blank" rel="noopener">NCT05397639</a> studied masupirdine for agitation in dementia of the Alzheimer’s type, while <a href="https://clinicaltrials.gov/study/NCT06852326" target="_blank" rel="noopener">NCT06852326</a> studied a tailored primary-care intervention for caregiver burden. Improving sleep, agitation, communication, caregiver support, home safety, daily function, or emotional strain is not a secondary concern. It is part of whether research respects daily life.</p>

<h2>From Phase 1 to Phase 4: What the Stages Actually Mean</h2>
<p>The <a href="https://www.fda.gov/patients/drug-development-process/step-3-clinical-research" target="_blank" rel="noopener">FDA explains that clinical research is done in people</a> and that trials are designed around a protocol: who qualifies, how many people participate, how long the study lasts, whether there is a control group, how the intervention is given, what assessments are collected, and how the data are reviewed. Phases describe the kind of question being asked; they are not a promise that an intervention will succeed.</p>

{figure(2)}

<table>
  <caption>Table 4. Trial phases in practical terms</caption>
  <thead>
    <tr>
      <th>Phase</th>
      <th>Main purpose</th>
      <th>What it can learn</th>
      <th>What it does not prove by itself</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Early Phase 1 / Phase 1</td>
      <td>Early safety, dose, tolerability, and how the intervention behaves in the body.</td>
      <td>Whether a dose is reasonable enough to study further and what side effects appear early.</td>
      <td>That the intervention improves memory, function, or disease progression.</td>
    </tr>
    <tr>
      <td>Phase 2</td>
      <td>Safety plus early evidence that the target, biomarker, dose, or clinical signal may be worth pursuing.</td>
      <td>Whether the intervention affects its intended biology or shows a manageable risk profile.</td>
      <td>That it will help a larger and more diverse population.</td>
    </tr>
    <tr>
      <td>Phase 3</td>
      <td>Larger tests of whether benefit is meaningful compared with placebo, sham, standard care, or another comparator.</td>
      <td>More robust evidence on clinical outcomes, biomarkers, and less common risks.</td>
      <td>That every eligible person will benefit or that long-term real-world questions are fully answered.</td>
    </tr>
    <tr>
      <td>Phase 4</td>
      <td>Questions after approval or broader clinical use.</td>
      <td>Longer-term safety, real-world effectiveness, monitoring, dosing, or use in different groups.</td>
      <td>That the treatment is right for every person with the diagnosis.</td>
    </tr>
    <tr>
      <td>Not applicable</td>
      <td>Often used for behavioral, diagnostic, device, observational, care, or other studies that do not fit drug-phase categories.</td>
      <td>Important evidence about detection, care, feasibility, behavior, or real-world outcomes.</td>
      <td>That the study is less rigorous simply because it has no drug phase.</td>
    </tr>
  </tbody>
</table>

<p>Other design terms matter too. <a href="https://clinicaltrials.gov/study-basics/glossary" target="_blank" rel="noopener">ClinicalTrials.gov’s glossary</a> is a useful place to check trial language. Randomization means participants are assigned by chance. A placebo or sham control helps researchers distinguish the intervention’s effect from expectation, attention, or natural change. Blinding means participants, clinicians, or outcome assessors may not know who received which assignment. Open-label extensions may let participants receive an active intervention after a blinded phase, but they are usually harder to interpret because everyone knows what is being given. Adaptive and platform trials can modify parts of a study using pre-planned rules, but they still need careful statistics and oversight.</p>

<h2>Why Some Trials Recruit People Before Symptoms Appear</h2>
<p>Earlier intervention is one of the clearest trends in Alzheimer’s research. If amyloid, tau, inflammation, vascular changes, and synaptic stress begin years before dementia, a trial that waits until later-stage symptoms may miss the window when biology is most changeable. That is why some trials enroll cognitively unimpaired people with biomarker evidence, people with elevated genetic risk, people with Down syndrome at elevated Alzheimer’s risk, or people with subjective cognitive concerns.</p>
<p>This is also why eligibility can feel demanding. A trial may require amyloid confirmation, tau testing, MRI, blood tests, cognitive testing, stable medications, no recent stroke, limits on anticoagulant use, or a reliable study partner. Those criteria are not arbitrary. They protect participants, reduce confounding, and help researchers answer a defined question. They can also make results less generalizable if enrolled participants do not reflect the broader community.</p>
<p>In the snapshot, participant-stage categories included 224 studies focused on MCI or prodromal Alzheimer’s, 112 on preclinical or elevated-risk groups, 123 on moderate or later dementia, and 222 involving care partners or care systems. Those categories overlap imperfectly with real life, but they show the field stretching from prevention to support.</p>

<h2>What Joining a Study Can Involve</h2>
<p>Participation varies widely. One study may be a single blood draw or survey. Another may involve years of visits, imaging, infusions, study medication, wearable devices, and care-partner interviews. The registry record is the starting point, not the whole conversation.</p>

{figure(4)}

<p>Common study steps can include an initial phone screen, review of medical history, medication review, cognitive testing, blood draws, genetic testing, MRI, PET imaging, lumbar puncture in some studies, infusions, injections, pills, device sessions, exercise or behavioral programs, study diaries, wearables, sleep monitoring, caregiver interviews, travel, randomization, placebo or sham assignment, and long follow-up. A person may not receive the active intervention. A person may not benefit personally. A person can ask what costs are covered, whether travel is reimbursed, what happens with incidental findings, and what support is available if side effects occur.</p>

<h2>How a Trial May Help, and What It Cannot Promise</h2>
<div class="article-impact-grid" aria-label="What Alzheimer’s clinical trials may and may not offer">
  <div class="article-impact-card">
    <h3>What a Trial May Offer</h3>
    <p>A study may offer specialist research assessments, closer monitoring, careful biomarker or cognitive evaluation, possible access to an experimental intervention, and the chance to contribute knowledge that helps future patients and families.</p>
  </div>
  <div class="article-impact-card">
    <h3>What a Trial Cannot Promise</h3>
    <p>A study cannot guarantee eligibility, active treatment, personal benefit, slower decline, returned test results, lower costs, or approval of the intervention being tested. It may also involve side effects, time, travel, privacy considerations, and emotional strain.</p>
  </div>
</div>
<p>This distinction matters because research participation is not treatment access alone. A well-designed study is valuable precisely because researchers do not already know the answer. Negative or inconclusive results can still prevent the field from chasing a weak idea, reveal safety concerns, improve trial design, or show that a biomarker change did not translate into daily-life benefit.</p>

<h2>How to Search for a Legitimate Alzheimer’s Study</h2>
<p>Start with authoritative resources. <a href="https://clinicaltrials.gov/" target="_blank" rel="noopener">ClinicalTrials.gov</a> provides the registry record, NCT number, recruitment status, eligibility criteria, locations, sponsor, intervention, phase, outcomes, and dates. The <a href="https://www.alzheimers.gov/clinical-trials/find-clinical-trials" target="_blank" rel="noopener">Alzheimers.gov Clinical Trials Finder</a> helps people search for studies related to dementia, memory problems, caregiving, and healthy aging. A neurologist, memory clinic, Alzheimer’s Disease Research Center, or primary medical team can help interpret whether a study is worth asking about.</p>
<p>When reading a registry record, look for the recruitment status, condition, eligibility, location status, sponsor, intervention, comparator, phase, primary outcomes, study duration, last update date, and NCT number. Avoid relying on a headline or advertisement. If a study claims guaranteed benefit, asks for unusual payment, hides the sponsor or protocol, or discourages discussion with a medical team, slow down.</p>

<h2>Important Questions to Ask Before Enrolling</h2>
<ul>
  <li>What is the main purpose of the study?</li>
  <li>Is it testing safety, biological effects, symptoms, disease progression, diagnosis, care, or feasibility?</li>
  <li>What procedures are required, and how often?</li>
  <li>Is there a placebo or sham group?</li>
  <li>What costs are covered, and is travel reimbursed?</li>
  <li>What happens if side effects occur?</li>
  <li>Can participants leave at any time?</li>
  <li>Will individual test results be returned?</li>
  <li>What information is shared with the participant’s regular clinician?</li>
  <li>What happens after the study ends?</li>
</ul>

<h2>What the Current Pipeline Says About Alzheimer’s Research</h2>
<p>The June 2026 landscape suggests a field moving beyond one target without abandoning biology that has already taught important lessons. Amyloid remained active. Tau, immunity, metabolism, synapses, vascular health, devices, lifestyle, biomarkers, and care were also visible. Biomarker-confirmed enrollment was changing who entered trials and what outcomes researchers could measure. Earlier intervention was increasingly common. Combination strategies were beginning to matter. More representative participation remained a practical and ethical need.</p>

{figure(5)}

<p>That larger picture should be hopeful only in a disciplined sense. Researchers had more tools, better biomarkers, and more ways to ask precise questions than they had in earlier eras. But a trial being active is not evidence that an intervention works. A biomarker moving in the desired direction is not the same as a person functioning better at home. A promising mechanism is not proof of safety or benefit. Clinical trials reduce uncertainty one structured question at a time.</p>

<h2>What We Can Honestly Say</h2>
<ul>
  <li>Alzheimer’s clinical research in June 2026 included far more than drug trials.</li>
  <li>Trial totals vary because different searches count different study types, statuses, stages, and conditions.</li>
  <li>In this conservative ClinicalTrials.gov snapshot, 878 active-status records met the June 10 cutoff rule, and 671 were in the participation-now subset.</li>
  <li>Some studies sought to slow disease biology, while others focused on symptoms, diagnosis, care, prevention, or trial readiness.</li>
  <li>An active trial is not proof that an intervention works.</li>
  <li>Participation can contribute important knowledge, but it cannot guarantee personal benefit.</li>
  <li>The best first step is to review the registry record and talk with both the research team and one’s medical team.</li>
</ul>
<p>Clinical trials are not promises. They are carefully organized questions asked with people, data, safeguards, uncertainty, and hope held in the same room. Each study tries to make one part of Alzheimer’s disease less uncertain. That work matters, even when the answer is not the one researchers hoped to find.</p>

<div class="article-wellness-tools" aria-label="Free wellness tools">
  <div class="article-wellness-tools__intro">
    <p class="eyebrow">Free wellness tools</p>
    <p class="article-wellness-tools__title">Choose a tool for your next healthy step</p>
    <p>Explore AI-guided learning, daily habit tracking, and practical prevention education from Mindful Diabetes.</p>
  </div>
  <div class="article-wellness-tools__grid">
    <a class="article-tool-card article-tool-card--jeir" href="https://www.mindfuldiabetes.ai/" target="_blank" rel="noopener">
      <span>JEIR</span>
      <strong>AI Wellness Guide</strong>
      <small>Ask clearer questions about blood sugar, insulin resistance, and brain health.</small>
    </a>
    <a class="article-tool-card article-tool-card--memovela" href="https://memovela.com/" target="_blank" rel="noopener">
      <span>Memovela</span>
      <strong>Wellness Tracker</strong>
      <small>Track movement, meals, sleep, hydration, stress, and daily check-ins.</small>
    </a>
    <a class="article-tool-card article-tool-card--game" href="https://www.jeir.fun/" target="_blank" rel="noopener">
      <span>Game</span>
      <strong>Mindful Eating Game</strong>
      <small>Practice nutrition choices in a quick, playful learning tool.</small>
    </a>
  </div>
  <div class="article-wellness-tools__resources">
    <a href="/memovela/">Read about Memovela</a>
    <a href="/diabetes-artificial-intelligence-jeir/">Read about JEIR AI</a>
    <a href="/health-tools/">Explore health tools</a>
  </div>
</div>

<h2>Keep Exploring</h2>
<p>Continue with <a href="/guide/">Pathways to Wellness</a>, revisit <a href="/ipsc-cells-alzheimers-disease-models/">human-cell Alzheimer’s models</a>, explore the <a href="/research/">Mindful Diabetes research hub</a>, or support our education work through the <a href="/donation/">donation page</a>. Clinical research is strongest when people can approach it with curiosity, good questions, and enough context to avoid both hype and dismissal.</p>
""".strip()


def image_brief() -> str:
    sections = [
        "# June 10, 2026 Blog Image Brief",
        "",
        f"Article: `{TITLE}`",
        f"Publication date: `June 10, 2026`",
        f"Slug: `{SLUG}`",
        "Folder: `static/uploads/2026/06`",
        "",
        "Visual style: warm, polished scientific editorial imagery for Mindful Diabetes; respectful clinical research scenes, soft daylight, green/coral/gold/navy accents, no readable text, no logos, no cure promises.",
        "",
    ]
    for index, image in enumerate(IMAGES, start=1):
        sections.extend(
            [
                f"## {index}. {image['title']}",
                "",
                f"Filename: `{image['filename']}`",
                f"Size: {image['size']}",
                f"Alt text: {image['alt']}",
                f"Title: {image['title']}",
                f"Caption: {image['caption']}",
                f"Description: {image['description']}",
                f"Intended placement: {image['placement']}",
                "",
                f"Prompt: {image['prompt']}",
                "",
            ]
        )
    return "\n".join(sections).rstrip() + "\n"


def main() -> None:
    items = json.loads(CONTENT_PATH.read_text(encoding="utf-8"))
    items = [item for item in items if item.get("slug") != SLUG]
    items.append(
        {
            "id": "5114",
            "type": "post",
            "slug": SLUG,
            "url": f"https://mindfuldiabetes.org/{SLUG}/",
            "status": "publish",
            "title": TITLE,
            "date": DATE,
            "modified": DATE,
            "excerpt_html": EXCERPT,
            "content_html": CONTENT_HTML,
            "featured_image_id": "alzheimers-clinical-trials-june-2026-hero",
            "parent": "0",
            "menu_order": "0",
            "template": "default",
            "categories": ["Blog"],
            "tags": [
                "Alzheimer’s research",
                "Clinical trials",
                "ClinicalTrials.gov",
                "Alzheimer’s clinical trials 2026",
                "Biomarkers",
                "Amyloid",
                "Tau",
                "Neuroinflammation",
                "Metabolism",
                "Caregiver research",
                "Mindful Diabetes guide",
            ],
            "seo_json": {
                "seo_title": "Alzheimer’s Clinical Trials in 2026: What Was Being Tested",
                "meta_description": "A June 10, 2026 snapshot of Alzheimer’s clinical trials, including trial counts, recruiting studies, locations, phases, interventions, participation, and limitations.",
                "canonical_url": f"https://mindfuldiabetes.org/{SLUG}/",
                "og_title": TITLE,
                "og_description": EXCERPT,
                "og_image": f"https://mindfuldiabetes.org/static/uploads/2026/06/{IMAGES[0]['filename']}",
            },
        }
    )
    CONTENT_PATH.write_text(json.dumps(items, indent=2, ensure_ascii=False) + "\n", encoding="utf-8")
    IMAGE_BRIEF_PATH.write_text(image_brief(), encoding="utf-8")


if __name__ == "__main__":
    main()
